MDM2 and cancer: RG7388 (idasanutlin), a second-generation MDM2 inhibitor, selectively disrupts the MDM2-p53 interaction through high-affinity binding to the p53 pocket of MDM2, thereby restoring wild-type p53 activity and promoting apoptosis in TP53WT cancers [9, 10].